123 related articles for article (PubMed ID: 18276068)
21. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
22. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action.
Damiano V; Garofalo S; Rosa R; Bianco R; Caputo R; Gelardi T; Merola G; Racioppi L; Garbi C; Kandimalla ER; Agrawal S; Tortora G
Clin Cancer Res; 2009 Nov; 15(22):6921-30. PubMed ID: 19903791
[TBL] [Abstract][Full Text] [Related]
23. Association with membrane protrusions makes ErbB2 an internalization-resistant receptor.
Hommelgaard AM; Lerdrup M; van Deurs B
Mol Biol Cell; 2004 Apr; 15(4):1557-67. PubMed ID: 14742716
[TBL] [Abstract][Full Text] [Related]
24. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2.
Nagy P; Vereb G; Sebestyén Z; Horváth G; Lockett SJ; Damjanovich S; Park JW; Jovin TM; Szöllosi J
J Cell Sci; 2002 Nov; 115(Pt 22):4251-62. PubMed ID: 12376557
[TBL] [Abstract][Full Text] [Related]
25. Anchoring of hyaluronan glycocalyx to CD44 reduces sensitivity of HER2-positive gastric cancer cells to trastuzumab.
Chen S; Zhang G; Liu Y; Yang C; He Y; Guo Q; Du Y; Gao F
FEBS J; 2024 Apr; 291(8):1719-1731. PubMed ID: 38275079
[TBL] [Abstract][Full Text] [Related]
26. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer.
Yotsumoto F; Oki E; Tokunaga E; Maehara Y; Kuroki M; Miyamoto S
Int J Cancer; 2010 Dec; 127(11):2707-17. PubMed ID: 20499311
[TBL] [Abstract][Full Text] [Related]
27. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
[TBL] [Abstract][Full Text] [Related]
28. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
Lu Y; Zi X; Zhao Y; Pollak M
Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
[TBL] [Abstract][Full Text] [Related]
30. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
[TBL] [Abstract][Full Text] [Related]
31. Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody.
Wang S; Chen C; Meng Y; Hu S; Zheng L; Song J; Zhang D; Li B; Guo Y
Cancer Lett; 2012 Dec; 325(2):214-9. PubMed ID: 22789781
[TBL] [Abstract][Full Text] [Related]
32. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
Arpino G; Gutierrez C; Weiss H; Rimawi M; Massarweh S; Bharwani L; De Placido S; Osborne CK; Schiff R
J Natl Cancer Inst; 2007 May; 99(9):694-705. PubMed ID: 17470737
[TBL] [Abstract][Full Text] [Related]
33. Differentiation of human airway epithelia is dependent on erbB2.
Vermeer PD; Panko L; Karp P; Lee JH; Zabner J
Am J Physiol Lung Cell Mol Physiol; 2006 Aug; 291(2):L175-80. PubMed ID: 16489114
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor modulates cell attachment to hyaluronic acid by the cell surface glycoprotein CD44.
Zhang M; Singh RK; Wang MH; Wells A; Siegal GP
Clin Exp Metastasis; 1996 May; 14(3):268-76. PubMed ID: 8674281
[TBL] [Abstract][Full Text] [Related]
35. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
[TBL] [Abstract][Full Text] [Related]
36. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance.
Liu D; Shi M; Duan C; Chen H; Hu Y; Yang Z; Duan H; Guo N
Mol Immunol; 2013 Nov; 56(1-2):104-12. PubMed ID: 23711387
[TBL] [Abstract][Full Text] [Related]
38. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
39. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.
Nagumo Y; Faratian D; Mullen P; Harrison DJ; Hasmann M; Langdon SP
Mol Cancer Res; 2009 Sep; 7(9):1563-71. PubMed ID: 19737968
[TBL] [Abstract][Full Text] [Related]
40. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
Kim WE; Serrero G
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]